CSGID applies state-of-the-art high-throughput (HTP) structural biology technologies to experimentally characterize the three dimensional atomic structure of targeted proteins from pathogens in the NIAID Category A-C priority lists and organisms causing emerging and re-emerging infectious diseases. The three dimensional structure of proteins will assist drug design and development by yielding direct insights into the target molecular mechanisms, in interaction with other biological molecules, or with synthetic compounds, in order to improve selectivity, specificity and optimize drug development in a rational way.